Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 4Phase NA 3Phase 3 3Phase 1/2 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 178Bortezomib 100Lenalidomide 90daratumumab 47Melphalan 46Thalidomide 44pomalidomide 43Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14isatuximab 12ixazomib 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × plerixafor × Plasma cell × Clear all
NCT01146834 2019-12-27

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Weill Medical College of Cornell University

Phase 3 Completed
47 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT01301963 2014-08-06

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Case Comprehensive Cancer Center

Phase 3 Terminated
9 enrolled 7 charts
Plasma cell

Multiple Myeloma

NCT00103662 2014-03-13

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Sanofi

Phase 3 Completed
302 enrolled 17 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡